Does reduced COMT activity increase pain sensitivity and risk of chronic pain?

Genetic variation in the catechol-O-methyltransferase (COMT) enzyme plays a significant role in modulating how the body processes pain. By regulating the degradation of catecholamines—dopamine, norepinephrine, and epinephrine—COMT activity directly influences the neurochemical environment of the central nervous system.

Clinical and effectiveness evidence

Low-activity variants of the COMT gene, particularly the well-studied rs4680 (Val158Met) polymorphism and specific "high pain sensitivity" (HPS) haplotypes, are consistently associated with heightened pain sensitivity.

• Experimental Pain Sensitivity: Meta-analyses show that carriers of the low-activity Met allele exhibit significantly lower pain thresholds and higher sensitivity to experimental stimuli, particularly in clinical populations.
• Chronic Pain Risk: Reduced COMT activity is a known risk factor for the development and severity of chronic pain phenotypes. Evidence strongly links these variants to fibromyalgia (FM) and temporomandibular disorders (TMD). For instance, the Met allele is associated with higher FM susceptibility and greater symptom severity as measured by the Fibromyalgia Impact Questionnaire (FIQ).
• Pain Chronicity: COMT variants appear to influence the transition from acute to chronic states, such as in low back pain or post-surgical contexts, by facilitating the persistence of pain signals.

Mechanistic explanations

The relationship between COMT and pain is driven by the prolonged presence of catecholamines in the synaptic cleft.

• Catecholamine Degradation: When COMT activity is low, catecholamines are degraded more slowly, leading to elevated tonic levels.
• Nociceptor Excitability: High levels of catecholamines can increase the excitability of nociceptors and impair descending inhibitory pathways that normally dampen pain signals.
• Central Sensitization: Elevated dopamine and norepinephrine signaling modulate pain-processing circuits in the anterior cingulate cortex and prefrontal areas. This promotes "central sensitization," a state where the nervous system remains in high-reactivity mode, amplifying both the intensity and duration of the pain experience.

Bottom line

Reduced COMT activity leads to elevated catecholamine signaling, which enhances nociceptive processing and central sensitization. This biochemical environment is strongly associated with increased experimental pain sensitivity and a higher risk of developing chronic pain phenotypes like fibromyalgia.